The Influence of China’s National Reimbursement on Clinical Development

Introduction

China’s National Reimbursement Drug List (NRDL) has become one of the most influential policy levers shaping clinical development strategies. Inclusion on the NRDL determines whether a drug is reimbursed under China’s basic medical insurance system, significantly affecting patient access and commercial success. For sponsors, the NRDL is no longer just a post-approval concern; reimbursement considerations are increasingly influencing trial design, therapeutic focus, and regulatory strategy. With annual NRDL negotiations that include price reductions of up to 60%, sponsors must carefully align clinical development with reimbursement priorities. This article explores how China’s reimbursement decisions impact clinical trials, covering regulatory frameworks, operational strategies, and global implications.

Background and Regulatory Framework

Historic Separation of Approval and Reimbursement

Historically, drug approval by the NMPA and reimbursement decisions were separate processes, with limited influence on each other. Many innovative therapies gained approval but remained out of reach for most patients due to high costs and lack of reimbursement.

Integration of NRDL and Clinical Development

Since healthcare reforms in 2017, NRDL inclusion has become a central determinant of a drug’s market potential. The National Healthcare Security Administration (NHSA) manages NRDL negotiations, requiring clinical evidence of safety, efficacy, and cost-effectiveness. This integration has created a feedback loop between clinical development and reimbursement.

Case Example: Oncology Drug NRDL Inclusion

An innovative oncology drug gained NMPA approval but initially struggled with sales due to high out-of-pocket costs. After NRDL inclusion in 2020, patient access expanded dramatically, with prescriptions increasing tenfold. The sponsor’s clinical trial design, which included pharmacoeconomic endpoints, was critical to NRDL acceptance.

Core Clinical Trial Insights

Trial Design with Reimbursement in Mind

Sponsors now design trials not only for regulatory approval but also for NRDL inclusion. This requires:
Collecting real-world evidence (RWE) alongside trial data
Incorporating pharmacoeconomic and quality-of-life endpoints
Targeting indications prioritized by public health policies (oncology, rare diseases, chronic diseases)
Demonstrating cost-effectiveness in Chinese patient populations
These strategies increase the likelihood of favorable NRDL negotiations.

Impact on Patient Recruitment

Reimbursement considerations affect recruitment strategies. Trials often focus on diseases prioritized by the NRDL, attracting patients eager for reimbursed therapies. Sponsors also collaborate with Tier-2 hospitals to ensure diversity and reflect real-world patient populations, improving NRDL acceptance.

Pharmacoeconomic Evidence Requirements

The NHSA requires pharmacoeconomic analyses as part of NRDL negotiations. Sponsors must provide data on incremental cost-effectiveness ratios (ICERs), budget impact, and quality-adjusted life years (QALYs). Clinical trial protocols increasingly incorporate these measures to strengthen reimbursement dossiers.

Role of Real-World Evidence (RWE)

RWE generated from Phase IV studies and hospital databases supports NRDL negotiations. Sponsors use RWE to demonstrate long-term safety, adherence, and economic value. Integration of RWE into trial planning enhances both regulatory and reimbursement outcomes.

Multinational Implications

China’s reimbursement-driven trial strategies are influencing global development. Sponsors increasingly design multinational trials with pharmacoeconomic endpoints to satisfy not only the NHSA but also HTA bodies in the EU and payers in the U.S. This creates a more integrated approach to global evidence generation.

Best Practices & Preventive Measures

Sponsors should:
Incorporate pharmacoeconomic endpoints early in trial design
Engage with the NHSA to understand NRDL priorities
Use RWE to complement clinical data
Align trial sites with regions prioritized for reimbursement access
Partner with CROs experienced in pharmacoeconomic data collection
These best practices increase the chances of NRDL inclusion and accelerate patient access.

Scientific & Regulatory Evidence

The NHSA’s NRDL negotiations draw on health technology assessment (HTA) principles similar to those used by NICE in the UK or IQWiG in Germany. The NMPA’s alignment with ICH E6(R2) GCP ensures trial quality, while pharmacoeconomic endpoints strengthen the reimbursement case. WHO guidelines on equitable access to medicines further support integrating clinical and economic evidence.

Special Considerations

Rare disease therapies face unique challenges, as high costs and small populations complicate reimbursement negotiations. Pediatric drugs also require tailored pharmacoeconomic models. Sponsors must address these considerations in trial planning and NRDL submissions.

When Sponsors Should Seek Regulatory Advice

Sponsors should engage the NHSA early in development to align trial designs with reimbursement expectations. Pre-submission consultations clarify pharmacoeconomic requirements, while joint engagement with the NMPA and NHSA ensures consistency between approval and reimbursement strategies.

Case Studies

Case Study 1: Chronic Disease Therapy

A multinational sponsor conducted a cardiovascular trial with pharmacoeconomic endpoints, including QALYs and hospital cost savings. The evidence supported successful NRDL inclusion in 2021, driving rapid uptake in China’s public healthcare system.

Case Study 2: Rare Disease Trial and NRDL Challenges

A rare disease therapy faced difficulty securing NRDL inclusion due to high treatment costs. By supplementing trial data with RWE from patient registries and negotiating patient assistance programs, the sponsor eventually gained conditional reimbursement, expanding access for affected patients.

FAQs

1. What is the NRDL in China?

The National Reimbursement Drug List is China’s official list of drugs reimbursed under the basic medical insurance system, managed by the NHSA.

2. How does NRDL inclusion affect clinical trials?

It influences trial design, endpoints, and recruitment strategies, as sponsors must generate evidence that supports reimbursement negotiations.

3. What evidence is required for NRDL negotiations?

Clinical efficacy, safety, pharmacoeconomic data (ICERs, QALYs), and real-world evidence are required for NRDL inclusion.

4. Do all approved drugs automatically enter the NRDL?

No, drugs must undergo NHSA negotiations, often requiring price reductions and strong evidence of cost-effectiveness.

5. How do NRDL decisions affect global sponsors?

They shape trial strategies, pushing sponsors to integrate pharmacoeconomic endpoints and RWE into multinational programs.

6. What therapeutic areas are prioritized for NRDL inclusion?

Oncology, chronic diseases, pediatric conditions, and rare diseases are often prioritized in negotiations due to public health needs.

Conclusion & Call-to-Action

China’s NRDL decisions have transformed clinical development, shifting reimbursement considerations from post-approval to early trial planning. For sponsors, success requires integrating pharmacoeconomic endpoints, engaging with the NHSA, and leveraging RWE to strengthen reimbursement dossiers. Organizations planning trials in China must align regulatory and reimbursement strategies to accelerate access and maximize market potential. By viewing reimbursement as a parallel goal to approval, sponsors can ensure both compliance and commercial success.